Furthermore, we have investigated the evidence supporting and opposing four key biomarkers of tissue reactions to Aβ being used as indirect biomarkers of Aβ pathology in AD diagnosis and clinical trials – GFAP, TREM2, p-tau, and NfL. This evidence concerns the gene NEFL and Alzheimer disease.